Contraindications and precautions to receiving influenza vaccine

Who should not receive the vaccine?

Influenza vaccination is contraindicated for individuals who have had documented anaphylaxis to any ingredient in the vaccine except egg, or a previous dose of inactivated influenza vaccine. These individuals should not receive the vaccine.

Influenza vaccination may be contraindicated or need to be delayed for people receiving some new cancer treatments

The immune-stimulant actions of atezolizumab (TECENTRIQ®), ipilimumab (YERVOY®), nivolumab (OPDIVO®), pembrolizumab (KEYTRUDA®) on the immune system increase a person’s risk of developing autoimmune conditions. It is not known whether receipt of an influenza vaccine whilst receiving these treatments or for up to six months after treatment increases a theoretical risk of triggering the occurrence of these side effects.

Please contact the person’s oncologist or 0800 IMMUNE (0800 466 863) for current advice about influenza vaccination for these people BEFORE administering the vaccine.

Please refer to the Medsafe website for the TECENTRIQ®, YERVOY®, OPDIVO® and KEYTRUDA® data sheets.